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Abstract: Natural killer (NK) cells are immune cells that can kill certain 
types of cancer cells. Adoptive transfer of NK cells represents a 
promising immunotherapy for malignant tumours; however, there is a 
lack of methods to validate anti-tumour activity of NK cells in vivo. 
Herein, we report a new chemiluminescent probe to image in situ the 
granzyme B-mediated killing activity of NK cells against cancer cells. 
We have optimised a granzyme B-specific construct using an 
activatable phenoxydioxetane reporter so that enzymatic cleavage of 
the probe results in bright chemiluminescence. The probe shows high 
selectivity for active granzyme B over other proteases and higher 
signal-to-noise ratios than commercial fluorophores. Finally, we 
demonstrate that the probe can detect NK cell activity in mouse 
models, being the first chemiluminescent probe for in vivo imaging of 
NK cell activity in live tumours. 
Immunotherapies, including treatments with genetically-
engineered cells or antibodies against immune checkpoint 
receptors, harness the cytotoxic potential of immune cells and 
show efficacy for the elimination of tumours.[1–6] Among these, the 
administration of natural killer (NK) cells after in vitro expansion 
has emerged as a promising immunotherapy. NK cells are innate 
immune cells with a protective role against viral infections and 
tumours. Clinical trials of adoptive transfer of NK cells have shown  
positive results in different types of cancer (e.g., acute myeloid 
leukemia and ovarian cancer)[7–11] but there are cases where NK 
cells are unable to eradicate tumours.[12] Functional imaging 
probes that could detect the activity of NK cells in tumours would 
help to identify optimal treatments in a patient-specific manner. 
 
Upon recognition of target tumour cells, NK cells release cytolytic 
granzymes into target cells, where they induce apoptosis.[13–15] 
The tumour-killing capacity of NK cells can be monitored in vitro 
by different methods. The gold standard method is a chromium 
release assay[16,17] where the levels of radioactive 51Cr from target 
cells -after lysis by NK cells- are measured. These assays have 
limited sensitivity, safety issues and are unable to detect early 
apoptosis. Flow cytometry has been used  to monitor NK cell 
cytotoxicity,[18–20] whilst  ELISA tests can quantify the release of 
cytokines  associated with NK cell function.[21] However, these 
methods have limited spatiotemporal resolution and are 
incompatible with in vivo imaging. Alternatively, imaging 
approaches including those relying on activatable probes[22–31] 
have opened an avenue for the acquisition of functional readouts 
in living organisms. To date, there are few chemical probes to 
directly report NK cell activity in tumours in vivo. 
Chemiluminescent luminophores are excellent scaffolds for the 
construction of highly sensitive probes because they do not 
require incident light. This feature enables detection of low 
concentrations due to minimal background. Recently, our groups 
have developed chemiluminescent agents utilising self-
immolative linkers that disassemble spontaneously to ‘turn on’ the 
emission of quenched chemiluminophores for the detection of 
proteases[32] and metabolites in preclinical models.[33,34] Herein we 
describe the first chemiluminescent probe to measure the activity 
of NK cells against cancer cells in vitro and in vivo. Our probe 
reacts with active granzyme B, a serine protease that NK cells 
deploy into cancer cells to induce apoptosis. Because the 
enzymatic activity of granzyme B is directly related to the cell 
death initiated by NK cells, this probe behaves as a direct reporter 
of the host’s immune cytotoxicity in tumours. We have rationally 
designed a probe whereby a granzyme B-specific substrate was 
coupled to an activatable phenoxydioxetane luminophore via a 
self-immolative linker so that chemiluminescence would be only 
detected in the presence of active granzyme B released by NK 
cells (Scheme 1).  
 
Scheme 1. Activation mechanism of the chemiluminescent probe 1. 
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We developed the peptide-based chemiluminescence probe 1 
utilising the sequence Ile-Glu-Pro-Asp (IEPD), which was 
reported by Thornberry et al as a substrate for granzyme B.[35] 
Previous reports on the IEPD sequence have shown its reactivity 
with granzyme B, enabling the development of granzyme B 
inhibitors as well as radiolabelled imaging probes for positron 
emission tomography.[36,37] Probe 1 is composed of 3 chemical 
moieties: 1) the granzyme B-cleavable peptide sequence Ac-
IEPD, 2) a self-immolative p-aminobenzyl alcohol (PABA) spacer 
including an electrophilic amide bond to favour enzymatic 
reactivity, and 3) a phenoxydioxetane moiety that emits 
chemiluminescence upon cleavage of the construct.  
 
We started the chemical synthesis of probe 1 by preparing the 
protected IEPD sequence using solid-phase peptide synthesis[38] 
(see Supplementary Information for synthetic details). The side 
chains of aspartic and glutamic acids were protected as allyl 
esters to isolate the peptide as a free carboxylic acid at the C-
terminus upon cleavage from the 2-chlorotrityl linker on 
polystyrene resin (Scheme 2). The carboxylic group of the 
tetrapeptide was then coupled to the aniline group of PABA using 
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) to 
render compound 2. Importantly, the PABA moiety accomplished 
two key functions: 1) to introduce a self-immolative spacer that 
could be cleaved by granzyme B favouring catalytic efficiency and 
preventing spontaneous decomposition of the chemiluminescent 
reporter,[32] 2) to increase the separation between Ac-IEPD and 
the phenoxydioxetane moiety and reduce steric hindrance at the 
cleavage site. Compound 2 was treated with chlorotrimethylsilane 
and sodium iodide to yield compound 3, which contained a 
reactive benzylic group for further substitution. Next, compound 3 
was reacted with the acryl-substituted phenol enol-ether to give 
the protected precursor 4. The allyl esters were deprotected using 
Pd(PPh3)4 and dimethyl barbituric acid (DMBA), and the resulting 
crude reacted with singlet oxygen -generated by methylene blue 
under light irradiation- to form the final dioxetane moiety. 
Purification by HPLC rendered the chemiluminescent probe 1 in 
>95% purity with an overall yield around 30%.  
 
With probe 1 in hand, we examined its chemiluminescence 
readout as function of time in the absence and presence and 
active human recombinant (hr)-granzyme B. As shown in Figure 
1, the incubation of probe 1 with the enzyme resulted in peptide 
cleavage -the rate-limiting step- (HPLC analysis in 
Supplementary Figure 1) and strong chemiluminescence 
emission around 520 nm within minutes and with very low 
background signals[39] (Figure 1a). The rapid response and almost 
background-free emission from probe 1 resulted in observed 
kinetic constants that appear more favourable than those 
previously reported for granzyme B-responsive fluorescent 
constructs (Supplementary Figure 2).[40–42] Furthermore, we co-
incubated probe 1 and the active enzyme in the presence of the 
granzyme B inhibitor Ac-IEPD-CHO.[43] The inhibitor decreased 
the chemiluminescence  by more than 90%, confirming that the 
activation of probe 1 is due to its reactivity with granzyme B 
(Figure 1a). Finally, we assessed the selectivity of probe 1 for 
granzyme B over other proteases (e.g., granzyme A, neutrophil 
elastase, caspases) as well as biomolecules that might cross-
react with the probe. Notably, probe 1 exhibited 139-fold 
chemiluminescence increase in less than 10 minutes after 
reacting with granzyme B, while we observed much smaller 
changes in chemiluminescence with other enzymes -detectable 
signals were only found with caspase 8- and biomolecules under 
the same conditions (Figure 1b). Altogether, these results indicate 
that probe 1 can rapidly monitor granzyme B activity with good 
selectivity over other biologically relevant analytes.   
 
Figure 1. a) Chemiluminescence spectra of probe 1 (100 μM) in aqueous buffer 
at 37 °C after incubation with hr-granzyme B (20 nM) (green line) or without 
enzyme (black line) under the same conditions. Competition experiments with 
granzyme B inhibitor (Ac-IEPD-CHO, 100 μM) are shown in red. Data as mean 
values (n=3). b) Chemiluminescence fold change of probe 1 (100 μM) after 
incubation at 37°C with serine proteases (20-40 nM; GZM B: granzyme B, 
CASP8: caspase 8, CASP9: caspase 9, GZM A: granzyme A, HNE: human 
neutrophil elastase) and other biomolecules (100 μM: GSH: glutathione, H2O2: 
hydrogen peroxide). Data as mean values±SEM (n=6-9). P values from ONE-
ANOVA tests with multiple comparisons. 
 
Scheme 2. Synthetic scheme for the preparation of the granzyme B-activatable probe 1. 
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Next, we compared the sensitivity of probe 1 to activatable 
fluorescent probes featuring the same peptide sequence. The 
commercially available fluorogenic probe Ac-IEPD-AMC contains 
the 7-amino-4-methylcoumarin moiety, which fluoresces at 450 
nm after cleavage by granzyme B (Figure 2a). We measured the 
signal-to-noise (S/N) ratios of probe 1 and Ac-IEPD-AMC after 
reaction with active granzyme B for 30 minutes. The ratios 
observed for probe 1 were higher than for Ac-IEPD-AMC and 
achieved S/N values around 100 in less than 10 minutes (Figure 
2b) whereas Ac-IEPD-AMC ratios were consistently under 5. 
Finally, we determined the limit of detection for granzyme B using 
probe 1 and obtained values around 0.7 nM, asserting the high 
sensitivity of this chemiluminescent construct (Supplementary 
Figure 3). Of note, these concentrations are within the dynamic 
range of  extracellular granzyme B reported in clinical samples,[44–
46] which highlights the potential of probe 1 for biomedical 
applications. 
 
Figure 2. a) Structure and activation mechanism for the fluorogenic probe Ac-
IEPD-AMC. b) Time-course signal-to-noise ratios after probe 1 (green bars, 100 
μM) and Ac-IEPD-AMC (blue bars, 25 μM) were independently incubated with 
hr-granzyme B (20 nM) in aqueous buffer at 37°C. Data as mean values±SEM 
(n=6).  
Given the excellent in vitro results, we examined whether probe 1 
could be used to detect granzyme B-mediated activity of NK cells 
against cancer cells under a PhotonImager™ luminescence 
imaging system. First, we assessed whether the imaging system 
could detect the signals derived from the reaction of probe 1 and 
the enzyme. Bright chemiluminescence was observed at 
increasing concentrations of probe 1, with the lowest 
concentrations of probe being detectable in the low micromolar 
range (Supplementary Figure 4). Next, we prepared in vitro co-
cultures of human NK-92 cells and the human breast 
adenocarcinoma cell line MDA-MB-231. Given previous reports of 
NK cell-based cytotoxicity assays,[47,48] NK-92 cells and MDA-MB-
231 cells were co-cultured in a 8:1 ratio and in the presence of 
interleukin-2 (IL-2), an essential cytokine for the survival, 
proliferation and activation of NK-92 cells.[49] Under these 
conditions, NK-92 cells induced apoptosis of MDA-MB-231 
cancer cells, as shown by fluorescence microscopy using a 
caspase 3 marker (Supplementary Figure 5). Cells were co-
incubated for different times, followed by the addition of probe 1 
and wash-free image acquisition (Figure 3a). Probe 1 showed 
very low emission in media as well as in NK-92 cells and MDA-
MB-231 cells alone; however, bright chemiluminescence was 
detected in the co-cultures of NK-92 and MDA-MB-231 cells 
(Figure 3 and Supplementary Figure 6). In line with the anti-
cancer activity of NK cells,[50] we observed that the 
chemiluminescence of probe 1 increased with the co-incubation 
time, with the brightest signals detected after 8 hours (Figure 3c). 
Furthermore, we verified that the chemiluminescence signals in 
the co-cultures were dependent on granzyme B activity as a 
significant reduction of the signals was observed upon addition of 
the Ac-IEPD-CHO inhibitor (Supplementary Figure 7). We also 
used antibody staining to image granzyme B in MDA-MB-231 
cells before and after co-culture with NK-92 cells and found that 
the levels of intracellular granzyme B were significantly increased 
after co-culture (Supplementary Figure 8). This observation 
suggests that NK-92 cells can release granzyme B in the 
proximity of MDA-MB-231 cells. Collectively, our results confirm 
that probe 1 provides a direct optical readout of NK cell activity 
against tumours via detection of active granzyme B, either in the 
extracellular milieu or intracellularly in target cancer cells. The 
speed and simplicity of this protocol may open new opportunities 
to assess the efficacy of NK cell-based anti-cancer treatments in 
patient biopsies. 
 
Figure 3. a) Representation of the co-culture chemiluminescence assay to 
measure granzyme B-mediated activity of NK cells against cancer cells. b) 
Chemiluminescence images of probe 1 (500 μM) incubated with either media 
only, MDA-MB-231 cells alone or co-cultures of MDA-MB-231 cells NK-92 cells 
for indicated times. c) Quantification of the chemiluminescence (in ph s-1) 
generated by probe 1 for different conditions. Data as means±SEM (n=3). P 
values from ONE-ANOVA tests with multiple comparisons. 
Finally, we examined the ability of probe 1 to image NK cell 
activity in vivo. We used a xenograft mouse cancer model where 
we injected immunocompromised NSG mice with human MDA-
MB-231 cancer cells to grow subcutaneous tumours on both 
flanks of the animals. NSG mice lack host NK cells, thus 
representing an optimal model to assess the efficacy of adoptively 
transferred NK-92 cells. First, MDA-MB-231 cells were injected to 
both flanks of the mice and grown for 3 weeks until two tumours 
(approx. 0.5-1 cm in diameter) were formed. At this point, NK-92 
cells cultured in the presence of IL-2 (2×106 cells/mouse) were 
injected into only one of the two tumours. Eight hours post NK cell 
transfer, probe 1 was administered to both tumours (i.e., tumours 
with and without NK cells) and whole-body imaging was 
performed immediately in a PhotonImagerTM system. As shown in 
Figure 4, bright chemiluminescence signals were detected only in 
tumours that had received NK cell injection. Probe 1 showed good 
stability in serum (Supplementary Figure 9) and produced very 
low chemiluminescence in tumours without NK cells. Moreover, 
no signals were detected in mice that had not been injected with 
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probe 1 (Figure 4). Tumours from NK-treated mice were 
harvested and imaged ex vivo to confirm that the 
chemiluminescence signal of probe 1 was derived from the 
presence of active NK cells in tumours (Supplementary Figure 10). 
The results obtained from this study highlight that probe 1 acts as 
a first-in-class chemiluminescent probe to image NK cell activity 
in live tumours in vivo. 
 
 
Figure 4. a) In vivo representative chemiluminescence images (from 3 
independent experiments) of NSG mice containing MDA-MB-231-xenograft 
tumours where NK-92 cells were adoptively transferred. In all mice, MDA-MB-
231 xenograft tumours were grown to 0.5-1 cm diameter in size. Left) only the 
right tumour (red arrow) was injected with NK-92 cells (2×106 cells/mouse) with 
the left tumour being NK cell-free. After 8 h of the NK cell injection, probe 1 (125 
g) was injected to both tumours. Right) control animal with no injection of probe 
1. Whole-body images were acquired immediately after injection of probe 1 and 
processed with M3Vision™ software. b) Quantification of chemiluminescence 
emission (ph s-1) for each condition displayed. Data as mean values±SEM (n=3). 
P values obtained from ONE-ANOVA tests with multiple comparisons. 
In summary, we have developed a new chemiluminescent probe 
for rapid and selective detection of NK cell activity in response to 
tumour cell recognition. We demonstrated that the activatable 
phenoxydioxetane reporter produces bright chemiluminescence 
after recognition by granzyme B but not with other closely related 
serine proteases. Probe 1 outperforms the commercial 
fluorogenic reagent Ac-IEPD-AMC in speed and signal-to-noise 
ratios and can be used to quantitatively measure NK cell function 
in co-cultures of human NK cells and cancer cells. Furthermore, 
we have used probe 1 in a preclinical mouse model of NK cell 
adoptive transfer where tumours that had been recognised by NK 
cells were visualized in vivo using whole-body 
chemiluminescence imaging. This study highlights the utility of 
activatable chemiluminescent probes to directly monitor the 
efficacy of NK cell-based immunotherapies in live tumours. 
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In vivo detection of NK cell activity against tumours was achieved with an activatable chemiluminescent probe containing a granzyme 
B-reactive peptide substrate linked to a phenoxydioxetane scaffold through a p-aminobenzyl alcohol linker. The rapid and specific 
chemiluminescence response of the probe was used to detect NK cell activity against breast cancer cells in living mice. 
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